Serum exocrine pancreas enzymes are biomarkers of immunotherapy response in new-onset type 1 diabetes
Our findings provide preliminary evidence that the exocrine pancreatic enzymes lipase and trypsin may be useful biomarkers of response to immunotherapy in type 1 diabetes. Further studies with larger numbers of participants are warranted.
Authors
- Rhonda L. Bacher (ORCID: https://orcid.org/0000-0001-5787-476X)
- Brittany Bruggeman (ORCID: https://orcid.org/0000-0002-5117-8031)
- Savanna Gornisiewicz (ORCID: https://orcid.org/0000-0002-1113-7868)
- Desmond Schatz (ORCID: https://orcid.org/0000-0002-1044-5762)
- Kieran McGrail
- Mark A. Atkinson (ORCID: https://orcid.org/0000-0001-8489-4782)
- Clive Wasserfall (ORCID: https://orcid.org/0000-0002-3522-8932)
- Martha Campbell‐Thompson (ORCID: https://orcid.org/0000-0001-6878-1235)
- Laura M. Jacobsen (ORCID: https://orcid.org/0000-0002-5144-7836)
- Michael J. Haller
Institutions
- University of Florida (US)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.3389/fendo.2024.1497373
- Citations
- 1
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.55
Funders
- Pediatric Endocrine Society
- Endocrine Fellows Foundation
- National Institute of General Medical Sciences
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences